Variable | N = 791 (100.0%) |
---|---|
Female sex (n; %) | 687 (86.9) |
Non-white race/color (n; %) | 313 (40.1) |
Age | |
 Mean ± SD | 54.7 ± 12.0 |
 Minimum; maximum | 21; 85 |
Age group (n; %) | |
  < 40 years | 89 (11.5) |
 40–49 years | 159 (20.5) |
 50–59 years | 257 (33.1) |
 60–69 years | 190 (24.4) |
  ≥ 70 years | 82 (10.5) |
Disease duration (years) | |
 Mean ± SD | 12.8 ± 8.9 |
 Minimum; maximum | 0; 56 |
Disease duration (categories) | |
  < 5 years | 135 (17.2) |
 5–9 years | 193 (24.6) |
 10–14 years | 183 (23.4) |
 15–19 years | 115 (14.7) |
 20–24 years | 78 (10.0) |
  ≥ 25 years | 79 (10.1) |
Increased WC (IDF) (n; %) | 288 (37.8) |
Increased WC (NCEP) (n; %) | 250 (32.6) |
BMI | |
 Mean ± SD | 27.1 ± 4.9 |
 Minimum; maximum | 17.0; 47.0 |
Overweight (BMI > 24.99 & < 30) | 514 (64.8) |
Obesity (BMI > 29.99) | 209 (26.9) |
Diabetes mellitus (n; %) | 119 (15.0) |
Systemic arterial hypertension (n; %) | 389 (49.2) |
Dyslipidemia (n; %) | 265 (34.3) |
Family history of CVD (n; %) | 129 (16.5) |
Smoking (n; %) | 93 (13.0) |
Use of methotrexate (n; %) | 531 (67.3) |
Use of prednisone (n; %) | 492 (62.6) |
Use of leflunomide (n; %) | 273 (34.5) |
Use of methotrexate + prednisone (n; %) | 226 (29.0) |
Use of methotrexate + leflunomide (n; %) | 44 (5.7) |
Use of prednisone + leflunomide (n; %) | 70 (9.0) |
C-reactive protein | |
 Mean ± SD | 20.2 ± 81.6 |
 Minimum; maximum | 0; 1730 |
C-reactive protein > 5 (n; %) | 395 (61.1) |
Rheumatoid factor (n; %) | 530 (75.0) |
DAS28 | |
 Mean ± SD | 4.07 ± 1.54 |
 Minimum; maximum | 0.0; 8.64 |
DAS28 (categories) (n; %) | |
 Remission | 123 (17.3) |
 Low activity | 102 (14.4) |
 Moderate activity | 302 (42.6) |
 High activity | 182 (25.7) |
ESR | |
 Mean ± SD | 28.2 ± 22.1 |
 Minimum; maximum | 0; 150 |
Metabolic syndrome | |
 NCEP (n;%) | 250 (32.6) |
 IDF (n;%) | 288 (37.8) |